2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08F.16 Re-Irradiation with Chemotherapy with/without Immunotherapy for In-Field Local Recurrence Among Lung Cancer Patients

EP.08F.16 Re-Irradiation with Chemotherapy with/without Immunotherapy for In-Field Local Recurrence Among Lung Cancer Patients

Back to course

Pdf Summary

This study explores the effectiveness of re-irradiation with chemotherapy, with or without immunotherapy, for patients experiencing in-field local recurrence of non-small cell lung cancer (NSCLC) after initial treatment. A total of 83 patients were analyzed retrospectively; 58 received re-irradiation combined with chemotherapy (termed re-RCT), and 25 received the same treatment followed by immune checkpoint inhibitors (re-RCIT).<br /><br />Key findings indicate that the median progression-free survival (PFS) was 5.6 months for the re-RCT group and 11.4 months for the re-RCIT group, a statistically significant difference (p = 0.031). Median overall survival (OS) showed less disparity, recorded at 17.9 months for the re-RCT group and 20.2 months for the re-RCIT group (p = 0.269). No significant differences were observed in survival rates across 1, 2, and 3 years, indicating comparable long-term survival outcomes between the two treatment approaches.<br /><br />Regarding safety, the study identified treatment-related adverse events (TRAEs), including pneumonitis, neutropenia, thrombocytopenia, and anemia. Both groups showed that these TRAEs were clinically acceptable and manageable, although heightened attention should be given to bronchial fracture or bleeding.<br /><br />The study concludes that combining radiotherapy with chemotherapy and ICIs can extend short-term survival more effectively than radiotherapy with chemotherapy alone. However, it does not significantly improve overall survival. The treatment regimen is deemed effective and safe for managing locally recurrent NSCLC, with an emphasis on managing bronchial complications.<br /><br />The research methodology included using statistical tools like the chi-square test, Kaplan-Meier method, log-rank test, and Cox regression model to compare and estimate survival times and potential prognostic variables, establishing a statistically significant p-value at less than 0.05.

Asset Subtitle

Soth Vannhong

Meta Tag

Speaker Soth Vannhong

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

re-irradiation

chemotherapy

immunotherapy

NSCLC

local recurrence

progression-free survival

overall survival

treatment-related adverse events

immune checkpoint inhibitors

bronchial complications